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Objectives This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary
arterial hypertension (PAH).
Background Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the endothelin type A re-
ceptor. The ARIES-1 (Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-
Controlled, Multicenter, Efficacy Studies) and ARIES-2 trials were the pivotal 12-week, placebo-controlled studies
that led to the regulatory approval of ambrisentan (5 and 10 mg) for the treatment of PAH.
Methods In the ARIES-1 and -2 studies, and the subsequent long-term extension protocol, the ARIES-E study, 383 patients
received ambrisentan (2.5, 5, or 10 mg). Efficacy and safety assessments are presented from the time of the
first dose of ambrisentan for all patients with post-baseline data.
Results After 2 years of ambrisentan exposure, the mean change from baseline in 6-min walk distance was improved
for the 5-mg (23 m; 95% confidence interval: 9 to 38 m) and 10-mg (28 m; 95% confidence interval: 11 to
45 m) groups. Estimates of survival and freedom from clinical worsening for the combined dose group were
94% and 83%, respectively, at 1 year and 88% and 72%, respectively, at 2 years. The annualized risk of amino-
transferase abnormalities 3 the upper limit of normal was 2% per year; most of these events were mild
and did not lead to discontinuation of drug.
Conclusions Two years of ambrisentan treatment was associated with sustained improvements in exercise capacity and a
low risk of clinical worsening and death in patients with PAH. Ambrisentan was generally well tolerated and had
a low risk of aminotransferase abnormalities over the 2-year study period. (A Long Term Study of Ambrisentan in
Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321; NCT00578786) (J Am Coll
Cardiol 2009;54:1971–81) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.033y
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sulmonary arterial hypertension (PAH) is a disease of the
ulmonary circulation characterized by a progressive eleva-
ion in pulmonary vascular resistance that leads to right
entricular failure and premature death. Although the num-
er of approved therapies for PAH has grown in the past 10
rom the *LA Biomedical Research Institute at Harbor-UCLA Medical Center,
orrance, California; †Cardiology Institute, University of Bologna, Bologna, Italy;
Medical University-Graz, Graz, Austria; §University of Texas Southwestern Med-
cal Center, Dallas, Texas; Baylor College of Medicine, Houston, Texas; ¶University
f Giessen Lung Center, Giessen, Germany; #University of Colorado, Denver,
olorado; **Mayo Clinic, Rochester, Minnesota; ††University of Michigan, Ann
rbor, Michigan; ‡‡University of Wisconsin, Madison, Wisconsin; §§Gilead Sci-nces, Inc., Boulder, Colorado; and  UCSD, La Jolla, California. This work was
unded by Gilead Sciences, Inc., Broomfield, Colorado. The authors have financial aears, the disease remains rapidly progressive with a poor
rognosis and approximately 50% mortality during the first
years after diagnosis (1–3).
Three signaling pathways involved in the pathogenesis of
AH have been targeted for therapeutic intervention: the
elationships with Gilead Sciences, Inc., the sponsor of the study. These relationships
nclude consultancy, membership on steering committees, and support for work as
nvestigators. The database and all statistical outputs were retained by the sponsor,
ilead Sciences, Inc. One statistician involved in the analysis (Mr. Despain) is an
mployee of the sponsor; however, these data were also reviewed by an independent
tatistician not affiliated with the sponsor (Dr. Roecker). Gerald Simonneau, MD,
erved as Guest Editor for this article.Manuscript received March 12, 2009; revised manuscript received July 8, 2009,
ccepted July 21, 2009.
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Long-Term Ambrisentan in PAH November 17, 2009:1971–81prostacyclin pathway, the nitric
oxide pathway, and the endothelin
pathway (4). Prostacyclin analogs
mimic the effects of prostacyclin,
an endogenous prostaglandin pro-
duced by the vascular endothe-
lium, to stimulate vasodilation of
the pulmonary arterial bed and
inhibit platelet aggregation (5).
Phosphodiesterase type 5 inhibi-
tors act to increase cytoplasmic
cyclic guanosine monophosphate
concentrations (the downstream
product of nitric oxide signaling)
and thus enhance nitric oxide–
mediated vasodilation of the vas-
culature (6). Endothelin receptor
antagonists (ERAs) act to dimin-
ish the downstream effects of en-
dothelin (ET)-1, the primary
member of a family of potent va-
soconstrictor peptides known to
lay an essential role in cardiovascular physiology and thought
o play a critical role in the pathogenesis and progression of
AH (7–10). Two receptor subtypes, endothelin receptor type
(ETA) and endothelin receptor type B (ETB), mediate the
ffects of ET-1. In humans, the ETA receptor is preferentially
xpressed in vascular smooth muscle cells and fibroblasts,
here it promotes the vasoconstrictive and mitogenic effects of
T-1 (11,12). In contrast, ETB receptors are found primarily
n the vascular endothelium, and activation of these receptors
esults in vasodilation via the production of nitric oxide and
rostacyclin (13,14). The ETB receptors also mediate the
learance of circulating ET-1 in the lungs, kidney, and liver
15). Thus, the ETA receptor represents a logical pharmaco-
ogic target.
Ambrisentan is an orally active, once-daily ETA-receptor
elective ERA that is currently approved (5 and 10 mg) in
he U.S., European Union, Australia, Canada, Norway,
celand, and Israel for the treatment of PAH. In 2 pivotal,
2-week, placebo-controlled studies (ARIES-1 [Ambrisen-
an in Pulmonary Arterial Hypertension, Randomized,
ouble-Blind, Placebo-Controlled, Multicenter, Efficacy
tudies] and ARIES-2), ambrisentan improved exercise
apacity along with other clinical indications of PAH
isease severity, including clinical worsening (16). The
RIES-E study was the long-term extension study for
atients in the ARIES-1 and -2 studies. The objective of
he ARIES-E study was to collect long-term safety and
fficacy data for PAH patients receiving ambrisentan.
ethods
linical studies. An integrated analysis of all patients who
eceived at least 1 dose of ambrisentan in the ARIES-1, -2,
Abbreviations
and Acronyms
6MWD  6-min walk
distance
ALT  alanine
aminotransferase
AST  aspartate
aminotransferase
ERA  endothelin receptor
antagonist
ET  endothelin
ETA  endothelin receptor
type A
ETB  endothelin receptor
type B
PAH  pulmonary arterial
hypertension
ULN  upper limit of
normal
WHO  World Health
Organizationr -E studies is presented. In the ARIES-1 study, 202 Tatients were randomized (1:1:1) to placebo, 5 mg am-
risentan, or 10 mg ambrisentan, whereas in the ARIES-2
tudy, 192 patients were randomized (1:1:1) to placebo, 2.5
g ambrisentan, or 5 mg ambrisentan. The ARIES-1 and
2 patient populations have been described previously (16).
n brief, these studies included patients with idiopathic
AH or PAH associated with connective tissue disease,
uman immunodeficiency virus infection, or anorexigen use.
t the time of screening, patients could not be receiving
RA, phosphodiesterase type 5 inhibitor, or prostacyclin
nalog therapy and were required to have serum amino-
ransferase (alanine aminotransferase [ALT] and aspartate
minotransferase [AST]) concentrations 1.5 the upper
imit of normal (ULN). Patients who completed the
RIES-1 or -2 study were eligible to receive long-term
mbrisentan treatment in the ARIES-E study. Patients who
eceived ambrisentan during the 12-week studies remained
n their current dose at enrollment into the ARIES-E
tudy, whereas patients who received placebo were random-
zed to ambrisentan treatment (ARIES-1: 5 or 10 mg once
aily; ARIES-2: 2.5 or 5 mg once daily).
The first 24 weeks of the ARIES-E study was a blinded,
xed-dose period; however, a single, blinded dose reduction
as permitted during this period in the event of study drug
ntolerance. After 24 weeks, the randomized treatment
ssignment remained blinded but dose adjustments were
ermitted per investigator discretion (available doses: 1,
.5, 5, and 10 mg).
Patients were assessed for safety and efficacy every 4
eeks during the 12-week placebo-controlled ARIES-1
nd ARIES-2 studies. In the ARIES-E study, safety and
fficacy were assessed at weeks 4, 12, 16, 24, 36, and 48, and
t 24-week intervals thereafter. Safety assessments included
onitoring of adverse events, clinical laboratory tests (every
weeks), vital signs, and physical examination. Female
atients of child-bearing potential underwent monthly urine
regnancy testing and were instructed to avoid pregnancy by
sing a double-barrier method of contraception.
Efficacy assessments included 6-min walk distance
6MWD), Borg dyspnea index, World Health Organiza-
ion (WHO) functional class, long-term survival, and time
o clinical worsening. Time to clinical worsening was
efined as the time from first dose of ambrisentan to first
ccurrence of death, lung transplantation, hospitalization
or PAH, atrial septostomy, addition of prostacyclin analog
herapy, study withdrawal because of the addition of other
AH drugs, or study withdrawal because of early escape. As
escribed previously, patients who met 2 or more pre-
efined criteria during the ARIES-1 or -2 study were
ligible to request early escape (after a minimum of 4 weeks
f blinded treatment) (16). Patients receiving placebo who
et early escape criteria were eligible to enroll in the
RIES-E study.
ata analysis. For all efficacy and safety assessments, baseline
as defined as the time of randomization to active study drug.
he analysis population included all patients who received at
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November 17, 2009:1971–81 Long-Term Ambrisentan in PAHeast 1 dose of ambrisentan in the ARIES-1, -2, or -E study.
or 6MWD, Borg dyspnea index, and WHO functional class,
he primary analysis was conducted using a last observation
arried forward imputation for missing data and included all
atients with post-baseline data. An analysis of observed data
ith no imputation for missing data (observed case) is also
resented as a sensitivity analysis. Sample size was based on the
umber of subjects that participated in the ARIES-1 and -2
tudies; therefore, there were no a priori estimates of power for
he various long-term assessments. Data are presented by
andomized ambrisentan treatment group, and descriptive
tatistics are presented without formal hypothesis testing.
Because of the visit schedule in the ARIES-E study, safety
nd efficacy data were assessed after the first year of treatment
t different intervals of ambrisentan exposure for patients who
nitially received ambrisentan or placebo in the ARIES-1 or -2
tudies. To account for these differences, analysis of 6MWD,
org dyspnea index, and WHO functional class included the
ollowing time points: baseline (immediately before first dose
f ambrisentan), 12 weeks, 24 weeks, 1 year (48 weeks), 1.5
ears (72 or 84 weeks), and 2 years (96 or 108 weeks). Safety
ata and Kaplan-Meier estimates of long-term survival, time to
linical worsening, time to ALT/AST3ULN, and time to
tudy discontinuation because of adverse events are presented
aseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
2.5 mg
(n  96)
Female sex 69 (72)
Age, yrs 52 15
Race
White 81 (84)
Black 0 (0)
Asian 1 (1)
Hispanic 14 (15)
Other 0 (0)
Weight, kg 72 16
WHO functional class
I 1 (1)
II 51 (53)
III 39 (41)
IV 5 (5)
Diagnosis
Idiopathic PAH 63 (66)
Associated PAH
Connective tissue disease 30 (31)
HIV infection 2 (2)
Drugs or toxins 1 (1)
6-min walk distance, m 350 87
Borg dyspnea index 4.1 2.7
Mean pulmonary artery pressure, mm Hg 50 14
Cardiac index, l·min1·m2 2.4 0.7
Pulmonary vascular resistance, mm Hg·l1·min1 10.4 5.3
Right atrial pressure, mm Hg 8.1 5.6alues are mean  SD or n (%). Baseline is defined as the time of first dose of ambrisentan. All hemody
HIV  human immunodeficiency virus; PAH  pulmonary arterial hypertension; WHO  World Healthhrough 1 year (52 weeks) and 2 years (104 weeks) of
reatment. For Kaplan-Meier analyses, patients who discon-
inued the study without experiencing an event were censored
t the time of discontinuation.
This study was conducted in accordance with the amended
eclaration of Helsinki. Local institutional review boards or
ndependent ethics committees approved the protocol, and
ritten informed consent was obtained from all patients.
esults
aseline characteristics. Baseline characteristics were sim-
lar across the 3 dose groups (Table 1). Overall, patients
ere mostly Caucasian (77%) and female (79%), with
diopathic PAH (63%) and WHO class II (43%) or III
46%) symptoms. The mean baseline 6MWD was 347 
5 m, and the mean Borg dyspnea index was 3.9  2.4.
atient disposition. A total of 383 patients received at
east 1 dose of ambrisentan (2.5 mg [n  96], 5 mg [n 
90], or 10 mg [n  97]) in the ARIES-1, -2, or -E studies
Fig. 1). This population included 350 patients who com-
leted the placebo-controlled period and enrolled in the
RIES-E study, 11 placebo patients who discontinued 1 of
he 12-week studies because of early escape and subse-
Treatment Group
5 mg
(n  190)
10 mg
(n  97)
All
(n  383)
154 (81) 79 (81) 302 (79)
51 14 49 17 51 15
148 (78) 65 (67) 294 (77)
5 (3) 6 (6) 11 (3)
6 (3) 2 (2) 9 (2)
29 (15) 22 (23) 65 (17)
2 (1) 2 (2) 4 (1)
71 17 75 22 72 18
7 (4) 4 (4) 12 (3)
77 (40) 35 (36) 163 (43)
91 (48) 48 (50) 178 (46)
15 (8) 10 (10) 30 (8)
119 (63) 59 (61) 241 (63)
60 (32) 34 (35) 124 (32)
7 (4) 2 (2) 11 (3)
3 (2) 2 (2) 6 (2)
348 87 342 81 347 85
3.8 2.3 3.8 2.1 3.9 2.4
48 14 50 15 49 14
2.5 0.8 2.6 0.7 2.5 0.8
11.2 7.3 11.0 5.8 11.0 6.5
8.0 4.8 8.8 5.3 8.2 5.1namic data are historical. All data are presented by randomized ambrisentan dose.
Organization.
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Long-Term Ambrisentan in PAH November 17, 2009:1971–81uently enrolled in the ARIES-E study, and 22 patients
ho received ambrisentan in 1 of the 12-week studies but
id not enroll in the ARIES-E study.
At 1 year, 315 patients remained on ambrisentan treatment,
ith 91% of these patients receiving ambrisentan mono-
herapy. At 2 years (Fig. 1), 261 patients were on ambrisentan
reatment, with 82% of these patients receiving ambrisentan
onotherapy, 10% receiving ambrisentan/sildenafil therapy,
% receiving ambrisentan/prostacyclin analog therapy, and 3%
eceiving ambrisentan/sildenafil/prostacyclin analog therapy.
n additional 22 patients discontinued from the study and
ransitioned to commercial drug before receiving 104 weeks of
mbrisentan therapy (study drug exposure range 75 to 102
eeks). Of these 22 patients, 19 had 2-year data collected for
MWD, Borg dyspnea index, and WHO functional class,
hereas the remaining 3 provided data collected through 1.5
ears of treatment.
Over the 2-year period, 42 patients died and 22 patients
iscontinued because of adverse events. The percentages of
atients who died during the 2-year period were 14%, 11%,
nd 8% for the 2.5-, 5-, and 10-mg groups, respectively.
he percentage of patients who discontinued therapy be-
ause of an adverse event was similar in the 3 dose groups
range 5% to 6%). Thirty-six patients discontinued therapy
ecause of reasons other than death or adverse event: clinical
tatus did not improve (n  9), withdrawal of consent by
atient (n  16), study procedure noncompliance (n  4),
ost to follow-up (n  2), did not enroll in extension study
n 3), or discretion of investigator (n 2). Similar results
Figure 1 Patient Disposition Through 2 Years of Treatment by
A total of 383 patients received at least 1 dose of ambrisentan (2.5 mg [n  96],
rial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Effic
discontinued because of early escape criteria. †Includes 3 patients who complete
transitioned to commercial ambrisentan after regulatory approval before week 104. §Iere observed by dose. bmbrisentan dose adjustments. As described above,
linded ambrisentan dose adjustments were allowed after
eek 24 of the ARIES-E study; however, over the 2-year
reatment period the majority of patients remained at their
andomized dose. At 1 year, the percentage of patients who
emained at their randomized dose was 89%, 87%, and 97%
or the 2.5-, 5-, and 10-mg groups, respectively. At 2 years,
hese percentages were 71%, 72%, and 97%, respectively. In
eneral, nearly all dose adjustments during the 2-year
reatment period were up-titrations in the 2.5-mg (28 of 28)
nd 5-mg (50 of 54) groups; only 3 dose reductions were
bserved in the 10-mg group.
xercise capacity. Figure 2A shows the change from base-
ine in 6MWD using the last observation carried forward for
issing data. After 1 year of ambrisentan treatment, im-
rovements in 6MWD were observed for all dose groups,
ith a change from baseline of 25 m (95% confidence
nterval [CI]: 5 to 45 m) for the 2.5-mg group,28 m (95%
I: 14 to 42 m) for the 5-mg group, and 37 m (95% CI:
2 to 52 m) for the 10-mg group. After 2 years of
mbrisentan treatment, improvements compared with base-
ine in 6MWD were maintained for the 5-mg (23 m; 95%
I: 9 to 38 m) and 10-mg (28 m; 95% CI: 11 to 45 m)
roups, whereas improvements in 6MWD did not seem to
e sustained in the 2.5-mg group at 2 years (7 m; 95% CI:
13 to 27 m). Similar results were observed when the data
ere analyzed with no imputation for missing data (ob-
erved case) (Fig. 2B). At 2 years, the mean change from
omized Dose
[n  190], or 10 mg [n  97]) in the ARIES-1 (Ambrisentan in Pulmonary Arte-
udies), -2, or -E studies. *Includes 4 patients in the ARIES-1 or -2 studies who
RIES-1 or -2 studies but did not enroll in the ARIES-E study. ‡Twenty-two patients
s 1 patient who transitioned to commercial ambrisentan at week 104.Rand
5 mg
acy St
d the A
ncludeaseline was 21 m (95% CI: 2 to 45 m) for the 2.5-mg
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November 17, 2009:1971–81 Long-Term Ambrisentan in PAHroup, 47 m (95% CI: 31 to 63 m) for the 5-mg group,
nd 38 m (95% CI: 19 to 57 m) for the 10-mg group.
dditional clinical end points. After 1 year of treatment,
ustained improvements in Borg dyspnea index were observed
or the 5-mg (0.59; 95% CI: 0.94 to 0.23) and 10-mg
0.51; 95% CI: 1.00 to 0.03) groups compared with
aseline (last observation carried forward) (Fig. 3); no improve-
ent in Borg dyspnea index was observed in the 2.5-mg group
0.08; 95% CI: 0.55 to 0.38). This trend continued
hrough 2 years of treatment, with a mean change from
aseline of 0.33 (95% CI: 0.68 to 0.03) for the 5-mg
roup,0.60 (95% CI:1.08 to0.11) for the 10-mg group,
nd 0.23 (95% CI: 0.31 to 0.76) for the 2.5-mg group.
Figure 2 Mean ( 95% Confidence Interval) Change From Baseli
(A) The 6-min walk distance (6MWD) with imputation of missing data using las
6MWD with no imputation of data (observed case only) for all patients in the a
below each graph.imilar results were observed at 2 years when the data were fnalyzed with no imputation for missing data: 2.5-mg group
0.28; 95% CI: 0.35 to 0.90), 5-mg group (0.53; 95%
I: 0.98 to 0.08), and-10 mg group (0.95; 95% CI:
1.45 to0.45). As shown in Table 2, WHO functional class
as either improved or maintained through 2 years for the
ajority of patients in each dose group (range 79% to 89%).
imilar trends were observed when the data were analyzed with no
mputation for missing data (range 86% to 90%; data not shown).
ong-term survival and clinical worsening. Overall, 42
atients died during the 2-year treatment period (Table 3).
ost patient deaths were classified by the investigators as
elated to the underlying PAH; the most frequent adverse
vents with an outcome of death were right ventricular
6MWD Through Year 2 by Randomized Ambrisentan Dose
rvation carried forward for all patients with post-baseline data. (B) The
s population. The number of observations at each time point is presentedne in
t obse
nalysiailure (3.1%), worsening pulmonary hypertension
(
M
(
9
e
(
P
9
y
b
w
p
1
7
t
(
7
y
s
(
t
h
w
p
(
e
7
A
A
S
t
r
e
(
t
g
1
m
e
d
t
W
V
(
1976 Oudiz et al. JACC Vol. 54, No. 21, 2009
Long-Term Ambrisentan in PAH November 17, 2009:1971–811.6%), and acute respiratory failure (1.0%). The Kaplan-
eier survival estimate for the overall population was 94%
95% CI: 91% to 96%) at 1 year and 88% (95% CI: 83% to
1%) at 2 years (Fig. 4). Similar results were observed within
ach dose group at 1 year (range 93% to 97%) and 2 years
range 85% to 91%) of treatment (Fig. 4). For the idiopathic
AH patient subgroup (n  241), survival was 96% (95% CI:
2% to 98%) at 1 year and 89% (95% CI: 84% to 93%) at 2
ears, whereas the estimated survival for this patient population
ased on the National Institutes of Health Registry formula
as 72% at 1 year and 61% at 2 years. Survival was similar in
atients with PAH associated with connective tissues disease at
year (91%; 95% CI: 84% to 95%) and 2 years (83%; 95% CI:
5% to 89%) compared with patients with idiopathic PAH.
After 1 year of treatment, 83% (95% CI: 79% to 87%) of
he overall population was free from clinical worsening
Kaplan-Meier estimate), whereas 72% (95% CI: 67% to
6%) of patients were clinical worsening event–free after 2
ears of treatment (Fig. 5). As with long-term survival,
imilar results were observed by dose group after 1 year
range 81% to 84%) and 2 years (range 70% to 73%) of
Figure 3 Mean ( 95% Confidence Interval) Change From Baseli
The number of observations at each time point is presented below the graph. BDI
HO Functional Class: Change From Baseline After 1 and 2 YearsTable 2 WHO Functional Class: Change From Baseline After 1
2.5 mg (n  94) 5 mg (n  187
1 Year 2 Years 1 Year
Improved 16 (17) 16 (17) 56 (30)
No change 68 (72) 58 (62) 122 (65) 1
Worsened 10 (11) 20 (21) 9 (5)
alues are n (%). Last observation carried forward analysis of WHO functional class change from
improved), 0 (no change), 1, 2, 3 (worsened). All data are presented by randomized ambrisentan dose.
Abbreviation as in Table 1.reatment (Fig. 5). During the 2-year treatment period,
ospitalization for PAH was the most common clinical
orsening event in all treatment groups (Table 3). A
ost-hoc analysis of time to clinical worsening by prior study
i.e., the ARIES-1 or -2 studies) showed similar 2-year
vent-free rates: ARIES-1, 5 mg (70% [95% CI: 59% to
8%]); ARIES-1, 10 mg (72% [95% CI: 62% to 80%]);
RIES-2, 2.5 mg (70% [95% CI: 59% to 78%]); and
RIES-2, 5 mg (76% [95% CI: 65% to 84%]).
afety. The most common adverse events during the 2-year
reatment period were peripheral edema, headache, upper
espiratory tract infection, and dizziness. Most peripheral
dema was mild (21%) or moderate (16%); however, 5
1.3%) patients experienced severe peripheral edema during
he 2-year observation period (1 patient in the 2.5-mg
roup, 2 patients in the 5-mg group, and 2 patients in the
0-mg group). One patient discontinued ambrisentan treat-
ent during the 2-year treatment period because of periph-
ral edema. The most common adverse events that led to
iscontinuation of ambrisentan or death during the 2-year
reatment period were right ventricular failure (3.9%), pul-
BDI Through Year 2 (Last Observation Carried Forward)
rg Dyspnea Index.
eatmentYears of Treatment
reatment Group
10 mg (n  96) All (n  377)
s 1 Year 2 Years 1 Year 2 Years
) 36 (38) 39 (41) 108 (29) 113 (30)
) 46 (48) 43 (45) 236 (63) 210 (56)
) 14 (15) 14 (15) 33 (9) 54 (14)
e for all subjects with post-baseline data. Categorical analysis with a 7-point scale: 3, 2, 1ne in
 Boof Trand 2
T
)
2 Year
58 (31
09 (58
20 (11
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November 17, 2009:1971–81 Long-Term Ambrisentan in PAHonary hypertension (3.7%), acute respiratory failure
1.0%), and cardiac arrest (0.8%). In general, similar results
ere observed in each of the dose groups, although there
eemed to be a greater percentage of patients who discon-
inued because of worsening pulmonary hypertension in the
.5-mg group (7.3%) as compared with either the 5-mg
2.1%) or 10-mg (3.1%) groups (Table 4).
For the overall study population, the estimated risk of
eveloping serum aminotransferase abnormalities (ALT/
ST 3 ULN) was 1.8% (95% CI: 0.8% to 3.9%) during
he first year of treatment and 3.9% (95% CI: 2.2% to 6.8%)
uring the cumulative 2-year treatment period (Fig. 6), for
n annualized risk of approximately 2%. Twelve patients
xperienced ALT/AST 3 ULN during the 2-year
eriod. For these 12 patients, the maximum ALT/AST
linical Worsening: Cumulative Incidence of Events Through 1 andTable 3 Clinical Worsening: Cumulative Incidence of Events Th
2.5 mg (n  96
1 Year 2 Ye
Patients with at least 1 clinical worsening event 17 (18) 27 (
Hospitalization for PAH 13 (14) 20 (
Death 3 (3) 13 (
Addition of approved prostacyclin analog therapy 5 (5) 7 (
Study withdrawal because of addition of other PAH therapy 4 (4) 4 (
Early escape 2 (2) 2 (
Atrial septostomy 0 (0) 0 (
Lung transplantation 0 (0) 0 (
alues are n (%). Patients can be included in more than 1 category of clinical worsening. Early esca
alk distance; 2) an increase of 1 or moreWHO functional class; 3) worsening right ventricular failur
dema); 4) rapidly progressing hepatic or renal failure; and 5) refractory systolic hypotension (sys
Abbreviations as in Table 1.
Figure 4 Kaplan-Meier Survival Analysis by Randomized Ambris
Kaplan-Meier survival analysis by randomized ambrisentan dose (dashed lines) and b
for years 1 and 2 (all treatment groups combined). The number at risk at each time pas 3 and 5 ULN for 10 patients and 8 ULN
or 2 patients. None of the 12 patients had concomitant
ilirubin 2 ULN, and only 2 patients discontinued
mbrisentan treatment because of aminotransferase ab-
ormalities. A reduction in mean hemoglobin concentra-
ion of 0.9 g/dl was observed at week 4, and this
eduction was largely maintained through 108 weeks of
mbrisentan treatment (1.2 g/dl). Reductions in mean
emoglobin at 2 years did not seem to be dose dependent
2.5 mg: 1.1 g/dl, 5 mg: 1.1 g/dl, 10 mg: 1.2 g/dl).
inimal changes in international normalized ratio (mean
SD) were observed over the course of the 2-year study
eriod (baseline: 2.13  1.37, week 108: 2.15  1.08).
here were no apparent effects of ambrisentan on war-
arin dose or dosing interval (data not shown).
ars of Treatment1 and 2 Years of Treatment
Treatment Group
5 mg (n  190) 10 mg (n  97) All (n  383)
1 Year 2 Years 1 Year 2 Years 1 Year 2 Years
28 (15) 47 (25) 16 (17) 25 (26) 61 (16) 99 (26)
22 (12) 35 (18) 13 (13) 21 (22) 48 (13) 76 (20)
12 (6) 21 (11) 5 (5) 8 (8) 20 (5) 42 (11)
9 (5) 18 (9) 4 (4) 9 (9) 18 (5) 34 (9)
3 (2) 3 (2) 1 (1) 1 (1) 8 (2) 8 (2)
1 (1) 1 (1) 2 (2) 2 (2) 5 (1) 5 (1)
0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 1 (1)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
defined by the presence of 2 or more of the following criteria: 1) a decrease of20% in the 6-min
dicated by increased jugular venous pressure, new/worsening hepatomegaly, ascites, or peripheral
od pressure 85 mm Hg). All data are presented by randomized ambrisentan dose.
Dose and by All Treatment Groups Combined
atment groups combined (solid line), with point estimates of survival shown
presented below the graph. ABS  all ambrisentan treatment groups combined.2 Yerough
)
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urrent medical therapies approved for the treatment of
AH have shown efficacy and safety in relatively short-term
12 to 18 weeks) randomized placebo-controlled studies.
ost long-term PAH studies to date, however, have been
onrandomized observational trials focused primarily on
ortality and safety, with very limited descriptions of
ost Common Adverse Events Leading toiscontinuation of Study, Study Drug, or Deathhrough 2 Years
Table 4
Mo t Common A verse Events Leading to
Discontinuation of Study, Study Drug, or Death
Through 2 Years
Treatment Group
2.5 mg
(n  96)
5 mg
(n  190)
10 mg
(n  97)
All
(n  383)
Right ventricular failure 3 (3.1) 7 (3.7) 5 (5.2) 15 (3.9)
Pulmonary hypertension 7 (7.3) 4 (2.1) 3 (3.1) 14 (3.7)
Acute respiratory failure 0 (0.0) 2 (1.1) 2 (2.1) 4 (1.0)
Cardiac arrest 1 (1.0) 2 (1.1) 0 (0.0) 3 (0.8)
Cardiorespiratory arrest 1 (1.0) 2 (1.1) 0 (0.0) 3 (0.8)
Pneumonia 1 (1.0) 1 (0.5) 1 (1.0) 3 (0.8)
Diarrhea 0 (0.0) 2 (1.1) 0 (0.0) 2 (0.5)
Dyspnea exacerbated 1 (1.0) 1 (0.5) 0 (0.0) 2 (0.5)
Hemorrhage intracranial 0 (0.0) 0 (0.0) 2 (2.1) 2 (0.5)
Hepatic enzyme increased 1 (1.0) 0 (0.0) 1 (1.0) 2 (0.5)
Hypoxia 0 (0.0) 0 (0.0) 2 (2.1) 2 (0.5)
Multiorgan failure 1 (1.0) 1 (0.5) 0 (0.0) 2 (0.5)
Pyrexia 0 (0.0) 2 (1.1) 0 (0.0) 2 (0.5)
Respiratory arrest 1 (1.0) 0 (0.0) 1 (1.0) 2 (0.5)
Sudden death 0 (0.0) 1 (0.5) 1 (1.0) 2 (0.5)
Syncope 2 (2.1) 0 (0.0) 0 (0.0) 2 (0.5)
Vomiting 0 (0.0) 2 (1.1) 0 (0.0) 2 (0.5)
Figure 5 Kaplan-Meier Analysis of Time to Clinical Worsening b
Kaplan-Meier analysis of time to clinical worsening by randomized ambrisentan do
for the years 1 and 2 risk of remaining clinical worsening event-free (all treatment
graph. ABS  all ambrisentan treatment groups combined.m
alues are n (%). Includes adverse events occurring in at least 2 patients. All data presented by
andomized ambrisentan dose.linical efficacy that are often restricted to selective post hoc
ubgroup analyses (2,17–21). Given that 6MWD has been
he primary end point for nearly all pivotal PAH trials,
urprisingly few long-term 6MWD data have been pub-
ished, and previous reports of long-term clinical efficacy
ave been primarily limited to completers analyses of
bserved data for patients who remained on therapy at a
ertain time point (1,22–25). Although informative, these
ypes of analyses can lead to overestimation of the treatment
ffect because they only include data for patients who have
uccessfully remained in the trial.
In 12-week placebo-controlled studies, the ETA-selective
RA ambrisentan improved several important clinical pa-
ameters in patients with PAH, such as exercise capacity
nd clinical worsening (16). The current study describes
ong-term clinical response, disease progression, survival,
nd safety over a 2-year treatment period for all patients
ho received ambrisentan in the ARIES trials.
Of the 3 doses of ambrisentan used in this long-term
tudy, the 2 higher doses (5 and 10 mg once daily)
eemed to provide a sustained benefit in exercise capacity
nd dyspnea, whereas the 2.5-mg dose seemed less
ffective. These results are consistent with the dose-
esponse trends that were observed for 6MWD in both of
he 12-week placebo-controlled studies and the regula-
ory approval of the 5- and 10-mg doses for use in PAH
atients.
Considering the progressive nature of the disease, it is
otable that most patients maintained or had an improve-
ent in WHO functional class and did not experience
linical worsening during 2 years of ambrisentan treat-
ndomized Ambrisentan Dose and All Treatment Groups Combined
shed lines) and all treatment groups combined (solid line), with point estimates
combined). The number at risk at each time point is presented below they Ra
se (da
groupsent. In the previous 12-week trials, a statistically
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November 17, 2009:1971–81 Long-Term Ambrisentan in PAHignificant improvement compared with placebo in the
re-defined end point of time to clinical worsening was
bserved in the ARIES-2 study but not in the ARIES-1
tudy (16); however, similar estimates of clinical worsen-
ng were observed for these study subpopulations during
his 2-year treatment period. This is most likely because
he differences in statistical significance previously re-
orted were largely caused by variability in the response
f the placebo groups in the ARIES-1 and -2 studies
91% and 78%, respectively), as similar responses were
bserved in these studies for patients receiving active
herapy (96% and 95%, respectively).
Kaplan-Meier estimates of 1- and 2-year survival in this
tudy were 94% and 88%, respectively. These survival estimates
re similar to the 1-year estimates previously reported by Benza
t al. (26) for patients with PAH treated with sitaxsentan
96%) and bosentan (88%), as well as by McLaughlin et al. (18)
nd Provencher et al. (20) (89%), although these latter reports
ere for idiopathic PAH patients only. In the long-term
ollow-up of the pivotal trials for bosentan, patients with
AH associated with connective tissue disease seemed to
ave worse long-term survival compared with patients
ith idiopathic PAH (73% vs. 89%, respectively) (18,25);
owever, higher estimates (92%) were reported by Den-
on et al. (27) for connective tissue disease patients
eceiving bosentan in a 53-patient open-label trial. In our
tudy, survival estimates were similar for patients with
diopathic PAH and patients with PAH associated with
onnective tissue disease treated with ambrisentan.
Because PAH is a progressive disease, it is not uncom-
Figure 6 Kaplan-Meier Analysis of Time to ALT/AST >3 ULN by
Kaplan-Meier analysis of time to ALT/AST 3 ULN by randomized ambrisentan d
mates for the years 1 and 2 risk of remaining ALT/AST 3 ULN event-free (all tr
ALT and AST 3 ULN at baseline before receiving the first dose of ambrisentan
sion, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies]
ambrisentan treatment groups combined; ALT  alanine aminotransferase; AST on for more than 1 PAH drug to be used when patients axperience clinical deterioration. However, during the
-year treatment period of this study, the majority of
atients remained at their randomized dose and received
mbrisentan monotherapy; thus, the persistence of clinical
enefit seen for the 5- and 10-mg dose groups seems to be
rimarily attributable to ambrisentan alone.
The safety profile of ambrisentan in this study was similar
o that seen in the ARIES-1 and -2 trials (16). Adverse
vents that led to discontinuation of therapy were infrequent
nd were generally consistent with disease progression.
eripheral edema, a known side effect associated with
RAs, did not seem to limit treatment because most cases
eported were mild to moderate and did not result in
iscontinuation of study drug.
In the 12-week ARIES-1 and -2 trials, no patients receiving
mbrisentan developed ALT/AST 3 ULN, compared
ith 3 (2.3%) patients receiving placebo (16). In this 2-year
ollow-up study, the annual incidence of aminotransferase
bnormalities was approximately 2% (16). Although this an-
ual incidence was low, 12 patients did experience elevations
3 ULN and 2 patients discontinued because of amino-
ransferase abnormalities; therefore, monitoring of liver func-
ion is still advised. Consistent with previous reports with
RAs (16,28) (Actelion Pharmaceuticals Ltd., Tracleer
bosentan] tablets, U.S. Food and Drug Administration drug
roduct label, 2009), a reduction in mean hemoglobin concen-
ration was observed with ambrisentan treatment. This reduc-
ion manifested within the first few weeks of drug initiation,
ith little additional change with long-term treatment. There-
ore, hemoglobin levels should be measured before initiation of
omized Ambrisentan Dose and All Treatment Groups Combined
ashed lines) and all treatment groups combined (solid line), with point esti-
nt groups combined). One patient was not included in this analysis because of
r placebo patient in the ARIES-2 [Ambrisentan in Pulmonary Arterial Hyperten-
The number at risk at each time point is presented below the graph. ABS  all
tate aminotransferase; ULN  upper limit of normal.Rand
ose (d
eatme
(forme
trial).
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Long-Term Ambrisentan in PAH November 17, 2009:1971–81dically thereafter. No clinically relevant changes in interna-
ional normalized ratio or warfarin dosage were observed in
his study. This observation is similar to what has been
bserved with bosentan (Actelion Pharmaceuticals Ltd., Tra-
leer [bosentan] tablets, U.S. Food and Drug Administration
rug product label, 2009), whereas increases in international
ormalized ratio and/or changes in warfarin dosage have been
eported with sitaxsentan, a known inhibitor of cytochrome
C9 (28,29).
This study was not placebo controlled because mono-
herapy studies longer than 12 to 16 weeks have not been
ppropriate in PAH patients; thus, it is not possible to
recisely estimate the long-term treatment effects of am-
risentan. However, in the ARIES-1 and -2 trials, the
lacebo groups deteriorated from baseline after 12 weeks,
nd considering the progressive nature of PAH, it is not
nreasonable to assume that these patients would have
ontinued to deteriorate with long-term placebo treatment.
herefore, the improvements observed in this long-term
tudy likely represent conservative estimates of treatment
ffect compared with what would be expected without
herapy (i.e., long-term placebo treatment).
As described earlier, previous studies that have examined
ong-term efficacy have generally reported observed data at
pecific time points (i.e., a completers analysis) with no
mputation for missing data (20,22,23). In this study, the
rimary analysis used a last observation carried forward ap-
roach for imputation of missing efficacy data. This approach
llows data to be analyzed for all patients who participated in
he study, not only patients who have remained on treatment.
owever, this approach is not without limitations. Although it
s true that patients who worsen while receiving treatment will
ave this decline incorporated into the analyses of subsequent
ime points, it is also true that patients may have further
eclined if they had continued to be assessed. In addition, this
pproach may not account for stable (or improved) patients
ho experience an acute worsening event (e.g., death) without
revious decline. Nevertheless, the observation that the 1- and
-year 6MWD was lower with the last observation carried
orward analysis than with the observed case analysis indicates
hat the last observation carried forward method represents a
ore conservative estimate of clinical benefit in this patient
opulation.
onclusions
he long-term use of ambrisentan over a 2-year period
esulted in sustained improvements in exercise capacity and
yspnea, a stabilization of WHO functional class, a low risk
f clinical worsening and death, and an acceptable safety
rofile that was similar to that seen in the 12-week placebo-
ontrolled trials. These data support the use of ambrisentan
s part of a long-term strategy for the treatment of patients
ith PAH.
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APPENDIX
or a complete list of investigators and centers in the ARIES-1 and -2 Study
for pulmonary arterial hypertension related to connective tissue dis- Group, please see the online version of this article.
